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Introduction
Sarcomas account for less than 1% of malignant
neoplasms arising in the head and neck in adults.1,2
These tumors are derived from the mesodermal tissue
with a diversity of clinical behaviors due to various
types of pathologic classifications. The classification of
sarcoma according to the anatomic location in the
head and neck region has proven helpful because of
the influence of location on decisions regarding  disease
management.1 However, previous articles have rarely
focused on sarcomas that originated in the larynx. The
paucity of cases and variety of tumor characteristics
make it difficult to analyze the treatment modalities
and outcomes in a large series.
The purpose of this study was to review the patients
with laryngeal sarcoma treated at our institute over a 20-
year period. The clinical presentation, histopathologic
features, treatment modalities, and outcome were
analyzed. The literature was also reviewed.
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Methods
Between 1980 and 2000, 1,389 patients with laryngeal
malignancies were registered in the database of the
Cancer Center, Taipei Veterans General Hospital.
Ten of the patients were diagnosed as sarcoma and the
main tumor was confirmed to originate from the
larynx. All of the patients were histologically proven to
be sarcoma. None of them had a history of irradiation.
The clinical records of the patients were reviewed
for demographic data, presenting symptoms, risk
factors, site of primary tumor, extension of local and
regional disease, treatment modalities, site and date of
recurrence, status, and date of last follow-up. As far as
we know, no specific staging system for laryngeal
sarcoma has been noted so far. The tumors were
staged retrospectively according to the American Joint
Committee on Cancer (AJCC) 2002 classification.3
All of the pathologic specimens were reviewed by a
single pathologist to evaluate histologic type, grading
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of tumor cells, status of surgical margins, perineural
invasion, lymphovascular invasion, and cartilage
invasion.
Clinical and pathologic data were entered into a
computer database (Microsoft Access 2000), and
statistical analysis was performed with a commercially
available software package (JMP 4.0; SAS Institute
Inc, Cary, NC, USA). The follow-up interval was
calculated in months from the date of initial diagnosis
until death or the date of last follow-up. For overall
survival (OS), patients were counted as being alive
or dead, regardless of the cause. For disease-specific
survival (DSS), patients who died of noncancer-
related causes were censored at the date of death.
OS and DSS were calculated by the Kaplan-Meier
method.
Results
Table 1 outlines the epidemiologic characteristics,
features of the tumors, treatment, posttreatment
functional status, and the outcomes of these patients.
There were 9 men and 1 woman, and the age at
diagnosis ranged from 18 to 76 years of age with a
median of 62. The site of the primary tumor was
the glottic region in 6 patients (60%), and the
supraglottic region in 4 patients (40%). Five patients
were T1, 3 were T2, 1 was T3, and 1 was T4. One
patient (10%) had cervical lymph node metastasis.
No patient had distant metastasis at presentation.
Five patients were stage I, 3 stage II, and 2 stage IV.
The initial presenting complaints varied, depending
on the location of the tumor. Hoarseness was the most
frequent complaint in our study. Five patients (50%)
had a history of tobacco use and 4 patients (40%) had
a history of alcoholic consumption.
The treatment modalities included surgery alone
in 5 patients, surgery combined with postoperative
radiotherapy (RT) in 4 patients, and RT alone in
1 patient. Conservation surgery with laryngeal
preservation was performed in 7 patients, including
endoscopic CO2 laser cordectomy in 3, vertical partial
laryngectomy in 2, and supraglottic laryngectomy
in 2. Total laryngectomy was performed in 2 patients.
Neck dissection was performed in 1 patient who
had a palpable cervical mass at advanced T4 stage.
Three patients received postoperative RT because of
positive surgical margin in 1 and high tumor cell
grading in 2. One patient had RT as the primary
treatment.
There were 8 histologic types in these cases. There
were 2 cases each of malignant fibrous histiocytoma
and hemangiosarcoma. The other types had only 1
case each. Histologic grading was determined as low,
intermediate, or high grade on the basis of
differentiation, cellularity, vascularity, amount of
stroma and necrosis, and the number of mitosis per 10
high-power microscopic fields. Four patients had
intermediate-grade tumor, 4 high grade, 1 low grade,
and 1 was unavailable. The surgical margins showed
6 negative margins, 1 close, and 2 positive. No case
had perineural or lymphovascular invasion. There
were 2 cases with thyroid cartilage invasion.
Table 1. Epidemiologic characteristics of patients, histology, details of treatment, and outcome
Case Age Sex Primary site Stage Histology Treatment
Type of Laryngeal
Outcome
surgery preservation
1 55 M Glottic T1N0M0 ChondroSa S TL No DNED at 239 months
2 65 M Glottic T1N0M0 CarcinoSa RT Yes DNED at 120 months
3 18 M Glottic T1N0M0 MFH S VPL Yes ANED at 123 months
4 21 M Supraglottic T2N0M0 HemangioSa S + RT SGL + ND Yes ANED at 91 months
5 65 M Supraglottic T2N0M0 HemangioSa S + RT Endo Laser Yes ANED at 94 months
6 49 M Supraglottic T2N0M0 MFH S SGL Yes DNED at 31 months
7 68 M Glottic T1N0M0 LeiomyoSa S Endo Laser Yes Local recurrence at 8 months;
ANED at 48 months
8 59 F Glottic T3N0M0 RhabdomyoSa S+RT VPL Yes ANED at 9 months
9 76 M Glottic T1N0M0 Mal giant cell tumor S Endo Laser Yes ANED at 122 months
10 70 M Supraglottic T4N2M0 FibroSa S+RT TL+ND No Died of distant
metastasis at 22 months
ANED = alive with no evidence of disease; CarcinoSa = carcinosarcoma; ChondroSa = chondrosarcoma; DNED = dead with no evidence of disease;
Endo Laser = endoscopic laser; F = female; FibroSa = fibrosarcoma; HemangioSa = hemangiosarcoma; LeiomyoSa = leiomyosarcoma; M = male;
Mal giant cell tumor = malignant giant cell tumor; MFH = malignant fibrous histiocytoma; ND = neck dissection; RhabdomyoSa = rhabdomyosarcoma;
RT = radiotherapy; S = surgery; SGL = supraglottic laryngectomy; TL = total laryngectomy; VPL = vertical partial laryngectomy.
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With a median follow-up period of 92 months
(range from 9 to 239 months), the 5-year OS and DSS
were 76% and 90%, and 10-year OS and DSS were 57%
and 90%, respectively. One patient had local recurrence
and 1 had distant metastasis to the lung. The patient
with local recurrence had a T1 glottic lesion, and
underwent endoscopic laser cordectomy with
undetermined margins. Tumor recurrence was noted
8 months after surgery. He received the second
endoscopic laser excision and kept disease-free over a
38-month follow-up. The patient with distant
metastasis had a T4N2bM0 supraglottic lesion. Tumor
recurrence was found 20 months after surgery. A
second primary tumor in the retroperitoneal region
was found in 1 patient, and the pathology proved to be
renal cell carcinoma.
Discussion
Sarcomas are malignancies derived from the
mesodermal tissue of the body. They are uncommon
neoplasms of the head and neck, accounting for less
than 1% of malignant tumors in this region and less
than 10% of all soft tissue sarcomas.1,2 According to
the report of the Memorial Sloan-Kettering Cancer
Center, less than 5% of soft tissue sarcomas in adults
occur in the head and neck, with the neck, face,
forehead, and sinuses as the common sites.4   Laryngeal
sarcoma has come to be regarded as rare, comprising
less than 1% of all laryngeal tumors.1 These neoplasms
display a diverse array of histologies and a wide
spectrum of clinical activity ranging from relatively
slow-growing lesions to aggressive locally and
regionally destructive lesions with the potential for
systemic metastasis. In addition, the anatomic and
pathophysiologic heterogeneity demonstrated by this
group of neoplasms demands that management
considerations be broad and multifactorial if a treatment
approach is to be effective.
Sarcoma of the head and neck commonly presents
as a painless submucosal or subcutaneous mass of
uncertain duration. Symptoms attributable to growth
vary according to the location. Those involving the
aerodigestive tract generally become symptomatic
earlier in the course of disease as compared with
tumors involving the neck. The early symptoms of
laryngeal sarcoma are a result of mechanical
interference with function, and depend on the size
and situation of the tumor growth. They are, as a
rule, insidious in onset and progression. Hoarseness
is usually the first symptom noted. Stridor and even
dyspnea follow in the course of time unless the tumor
is removed at its early stages. Dysphagia is not likely
to be a prominent symptom, especially at the early
stage, until it becomes large enough and protrudes
into the hypopharynx.5
Laryngeal sarcomas are important in the differential
diagnosis for laryngeal submucosal masses. Physically,
the neoplasms are often pedunculated and they may be
lobulated. Ulceration does not ordinarily develop,
which is in contrast with the early ulceration commonly
present in carcinoma of the larynx. Sarcomas may
originate in any part of the larynx, but, like carcinoma
of this organ, it is most often primarily situated in the
vocal cords.4,5 It is usually more definitely localized
and less likely to infiltrate. Clinically, crossing of the
anterior commissure and involvement of the
contralateral side is infrequently noted.
The etiology of laryngeal sarcoma is obscure so far.
The probable relationship of various forms of chronic
irritation has never been assumed. Sarcoma of the
larynx is observed much more frequently among males
than females. The elderly group predominates.6 In our
cases, only 1 female was noted and the median age was
62 years. This is compatible with the demographic
findings of previous studies for sarcomas.
Neither the symptoms nor the physical findings are
sufficiently characteristic in cases of laryngeal sarcoma
to permit a clinical diagnosis. An accurate diagnosis
depends on careful biopsy under a laryngoscope. It is
important to get the core of tissue and not only the
superficial tumor. Complete study by an experienced
pathologist and extensive immunohistochemistry tests
to distinguish various types of soft tissue sarcomas are
usually required.5
There is no standardized staging system for soft
tissue sarcomas of the head and neck or for the larynx.
The Task Force on Soft Tissue Sarcoma of the AJCC
evolved in 19682,7 and most authors (Table 2) consider
5 cm (< 5 cm is T1, and * 5 cm is T2) as the reference
size for tumor staging according to the TNM system
with a grade of tumor (G) added.2,7,15 For laryngeal
sarcomas, due to their complex and unique anatomic
sites, no specific staging system is valid. Therefore, in
this study, we used the AJCC staging system for
laryngeal tumors to stage our cases.
Treatment of sarcomas is dictated by tumor type,
staging, location, size, and patient age.16 The treatment
planning for sarcoma of the larynx depends on its size,
situation, and biologic behavior. Because many of
these tumors are pedunculated, show less tendency to
infiltrate the surrounding structures, and metastasize
later than laryngeal carcinomas, they may remain
operable for a considerably longer period after
diagnosis compared to squamous cell carcinoma.17
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Actually, many of them at the early stage may be
removed readily just by means of a direct laryngoscope.
If the tumor is too extensive to remove in this
manner, laryngectomy may be necessary.17 In our
study, 9 patients received surgery, including 2 total
laryngectomy, 5 partial laryngectomy, and 3 who
had removal of tumors by means of endoscopic laser.
Only 1 patient received a full course of radiation
therapy as the main treatment because of small lesions
and old age at diagnosis, and which eventually resulted
in a good prognosis. Surgery is the mainstay therapy
in treatment planning for laryngeal sarcomas. Organ
preservation is possible because most patients can be
diagnosed early.
The literature shows that 10–12% of soft tissue
sarcomas of the head and neck develop neck metastasis
early;18 however, it is not common in laryngeal
sarcomas, except at advanced stages. In the case of
fibrosarcoma, which is found most frequently, even
the poorly differentiated type metastasize in fewer
than 25% of patients.19 Elective neck dissection is
generally not required. In our series, only 1 patient
with a palpable neck mass had neck dissection (10%),
which proved to be a neck metastasis.
The role of RT in the treatment of sarcomas of
the head and neck has evolved considerably over the
past 30 years. Although, in many instances, sarcomas
demonstrate considerable radio-resistance, RT
remains an important adjunct in the treatment of soft
tissue sarcoma to diminish the incidence of local
recurrence.13 The major indications for postoperative
RT are high-grade lesions, positive surgical margins,
larger tumor (> 5 cm) and recurrent lesions.20 In our
cases, adjunctive postoperative RT was administered
in 4 patients with high-grade tumors to achieve better
local control. On the other hand, the effect of
chemotherapy to various laryngeal sarcomas has not
been documented statistically. None of our patients
received chemotherapy, although established
nonsurgical protocols involving chemotherapy and
RT have been standardized for rhabdomyosarcoma.21,22
With these treatment modalities, treatment failure
was noted in 2 patients: 1 patient had local recurrence
(leiomyosarcoma, high grade) after endoscopic laser
surgery; the other with a T4 lesion eventually had
distant lung metastasis (fibrosarcoma, high grade).
These 2 cases had the common feature of high-grade
tumors, although the former case was categorized as
early T stage when diagnosed.
In most series of head and neck soft tissue
sarcomas,8,9,19,23,24 local control relative to grade
and margin status, together with the development
of distant metastasis, was the most influential
determinant of survival in this heterogeneous group
of tumors.8 Different pathologic classifications may
also influence the prognosis. Certain pathologic
kinds of soft tissue sarcomas are often associated with
high histologic grading, such as malignant fibrous
histiocytoma and rhabdomyosarcoma,8,19,23 and
usually indicate poor prognosis clinically. In contrast,
chondrosarcoma is usually well differentiated
pathologically and brings better prognosis.9 As in
head and neck malignancies, patients with recurrent
local disease are at risk for developing disseminated
sarcoma, and the most common site is in the lungs.19
This is particularly true in patients with high-grade
lesions, even if evidence of primary local recurrence
is not established. For this, high-grade tumors warrant
adjunctive postoperative RT in the treatment
planning.20
In general, the survival rate of sarcomas in the head
and neck is worse than if they are found in the
extremities. In reviewing the literature, 5-year OS of
patients with soft tissue sarcoma of the head and neck
Table 2. Review of literature on sarcoma of the head and neck
Author Site of primary tumor Pathologic type No. patients 5-year OS
Farr, 19818 Head and neck region Soft tissue sarcoma 285 32%
Littman et al, 19839 Head and neck region Soft tissue sarcoma 32 75%
Lavertu and Tucker, 198410 Larynx Chondrosarcoma 46 77%
Farhood et al, 19901 Head and neck region Soft tissue sarcoma 176 55%
Kowalski and San, 199411 Head and neck region Soft tissue sarcoma 128 48%
Eeles et al, 19932 Head and neck region Soft tissue sarcoma 103 50%
Tran and Parker, 199212 Head and neck region Soft tissue sarcoma 164 66%
Le et al, 199713 Head and neck region Soft tissue sarcoma 65 56%
Dudhat et al, 200014 Head and neck region Soft tissue sarcoma 72 60%
VGH in Taipei, 2001 Larynx Sarcoma 10 76%
OS = overall survival rate.
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ranged from 32% to 75% (Table 2).1,2,9-14,25 Because of
the rarity of laryngeal sarcoma, no convincing data
about survival have been available so far. One series
that focused on laryngeal chondrosarcoma revealed
similar survival to ours (77% vs 76% ).9 The 5-year OS
was about 50% for well-differentiated laryngeal
fibrosarcoma in a previous series.19 It seems that the
prognosis of laryngeal sarcoma is somewhat better
than that of sarcoma in other sites of the head and
neck.10,11,25
To head and neck surgeons, sarcoma of the larynx
is an uncommon neoplasm. Surgical intervention has
been considered as the treatment of choice. Because
most of the patients can be diagnosed early,
conservation surgery with laryngeal preservation is
usually possible. Postoperative adjuvant RT is only
reserved for a high-grade tumor and positive surgical
margins. The prognosis is relatively good when
compared with a tumor originating from other
anatomic sites.
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